Clinical Trial Update: GISSI-HF- Effects of n-3 PUFA and Rosuvastatin on Mortality-Morbidity of Patients With Symptomatic CHF [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating the combined effects of omega-3 polyunsaturated fatty acids and rosuvastatin on mortality and morbidity in symptomatic heart failure; t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure

Drugs mentioned

• Omega-3 polyunsaturated fatty acids (omega-3 polyunsaturated fatty acids)
• Rosuvastatin (rosuvastatin)

Snippet

Sponsor: Gruppo di Ricerca GISSI | Conditions: Heart Failure | Phase 3 | Status: COMPLETED